Podcast: Drivers of the Hyperepidemics of HIV in South Africa: Pt. 2, Biological Risk Factors

CSIS

Professor Quarraisha Abdool Karim is one of the world’s leading AIDS researchers and has made pioneering contributions to understanding the HIV epidemic in young people, especially among young women. She joined us for a two-part series to explain her latest research into epidemic hot spots in KwaZulu-Natal in South Africa, focusing on both the structural and biological risk factors that facilitate the spread of HIV in young women. In Part 2, she describes her recent findings about biological factors that can simultaneously increase a woman’s risk of HIV acquisition and decrease the efficacy of HIV prevention tools.

February 12, 2019
Year of publication
2018
Resource types
Video and audio clips
Countries
Tags
gender, young women and girls, oral PrEP, biological risk, treatment efficacy

Similar Resources

Antiretroviral medications that are used as prophylaxis can prevent acquisition of human immunodeficiency virus type 1 (HIV-1) infection. However, in clinical trials among African women, the incidence of HIV-1 infection was not reduced, probably because of low adherence.

Many countries are working to reduce or eliminate mother-to-child transmission (MTCT) of HIV. Prevention efforts have been conceptualized as steps in a cascade but cascade completion rates during and after pregnancy are low.

Female sex workers (FSW) in sub-Saharan Africa have a higher prevalence of HIV than other women of reproductive age. Social, legal, and structural barriers influence their access to care. Little is known about the HIV diagnosis and care cascade in most countries in southern Africa.

Remarkable progress is being made on HIV treatment. Ahead of World AIDS Day, UNAIDS has launched a new report showing that access to treatment has risen significantly. In 2000, just 685 000 people living with HIV had access to antiretroviral therapy.

The Partnership for HIV-Free Survival (PHFS) was designed to use basic quality improvement practices to reduce mother-to-child transmission of HIV and increase child survival through improvements in (1) antiretroviral therapy uptake and retention among HIV-positive pregnant women and mothers, (2)

An essential first step in caring for HIV-infected children is accurate and early diagnosis of HIV, early HIV testing, prompt return of results, and rapid initiation of treatment.

USAID’s Office of HIV/AIDS (OHA) and the Center for Innovation and Impact (CII) are excited to announce the launch of “V”, a human-centered design approach to addressing challenges in uptake and adherence for oral PrEP among adolescent girls and young women.

We conducted a longitudinal and cross-sectional analysis of depressive symptomology in iPrEx, a randomized, placebo-controlled trial of daily, oral FTC/TDF HIV pre-exposure prophylaxis (PrEP) in men and transgender women who have sex with men.

Timely access to antiretroviral treatment (ART) is vital to ensuring safe motherhood and reducing vertical transmission. Treatment guidance and programming has changed dramatically in recent years.

We conducted a retrospective study to investigate the effectiveness of an mHealth messaging intervention aiming to improve maternal health and HIV outcomes.